sábado, 14 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 22, 2026

How the Supreme Court tariff ruling tests Fed independence

View original at finance.yahoo.com
How the Supreme Court tariff ruling tests Fed independence The bitter clash over global tariffs has exposed more than a deepening U.S. trade policy dispute from Main Street to Wall Street…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • American consumers will be made better off by tariffs in the long run

    80% confidence
  • New York Fed research was shoddy and wouldn't be accepted in a first semester econ class

    80% confidence
  • Fed will remain firmly independent; should never confuse selection with independence

    80% confidence
  • New York Fed tariff study reinforces Fed's independence and signals economic assessments are grounded in data rather than political pressure

    80% confidence
  • While U.S. has experienced moderating inflation, it will be range-bound for near future; further rate reductions will be on hold for first half of 2026

    80% confidence
  • American importers and consumers bear nearly the entire cost of the 2025 tariffs

    80% confidence
  • White House dispute on tariff study is really about monetary policy; Fed is doing best to make best assessment of economy based on data and analysis

    80% confidence
  • U.S. firms and consumers continue to bear the bulk of the economic burden of the high tariffs imposed in 2025, approximately 90%

    80% confidence
  • 30% of the 2025 tariffs would be absorbed by businesses and 70% passed on to consumers

    80% confidence
  • White House attacks on New York Fed study are just another step to try to compromise the Fed's independence; over the past year there have been multiple attempts

    80% confidence
  • Potential of Fed losing independence would not be good for U.S. equity and bond markets, especially if Federal Funds Rate were cut dramatically

    80% confidence
  • While Fed independence loss might help boost U.S. economy in short term, longer-term implications are negative including inflation returning, capital flight, lower dollar, equity declines, and credit spread widening

    80% confidence
  • After Supreme Court ruled tariffs illegal, U.S. government may have to refund estimated $168 billion; $259 billion in tariff revenue collected since April

    80% confidence
  • New York Fed tariff study is an embarrassment and the people associated with it should be disciplined

    80% confidence
  • Role of Fed will change because it needs to change, and will be more aligned with current administration; this is nothing new

    80% confidence
  • Tariff pass-through to U.S. import prices is almost 100%, so the United States is bearing a large share of the costs

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,580 documentos-fonte arquivados
Consulte estes dados → isubstrate.com